Click here for slides on this topic


A1C

A minor component of hemoglobin to which glucose is bound.
The following content matched the glossary term: A1C

Poor Glycemic Control Linked With Dementia

Top

Poor glycemic control was associated with an increased risk for dementia in a new study of type 2 diabetes patients presented at EASD 2015.

Better Glucose Control With Liraglutide Over Lixisenatide

Top

Liraglutide lowers A1C more than lixisenatide in a head-to-head study of type 2 diabetes patients presented at EASD 2015.

AHA ADA prevention of CVD in T2D - Glycemic Targets

Top

Summary of glycemic target recommendations, including A1C goals, from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

AHA ADA prevention of CVD in T2D - Diabetes Diagnosis

Top

Summary of criteria for diabetes diagnosis from the AHA ADA cardiovascular disease (CVD) prevention in type 2 diabetes guidelines.

NDEI.org Expert Commentary Silvio E. Inzucchi MD on Type 2 Diabetes Treatment Recommendations

Top

EXPERT COMMENTARY New Silvio E. Inzucchi, MD, on Phentermine Plus Topiramate for Weight Loss in Type 2 Diabetes   Silvio E. Inzucchi, MD  Weight loss remains a great challenge for our patients, especially those with type 2 diabetes. While lifestyle

AACE 2015 guidelines Glycemic Targets

Top

Summary of glycemic treatment targets, including the A1C goal, from the 2015 AACE diabetes guidelines 

NDEI.org Expert Commentary Phentermine-topiramate for weight loss in type 2 diabetes Silvio Inzucchi

Top

EXPERT COMMENTARY Expert blog post from Silvio E. Inzucchi, MD: "Weight loss remains a great challenge for our patients, especially those with diabetes."

ADVANCE-ON: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

Top

Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;[epub ahead of print]. doi: 10.1056/NEJMoa1407963.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: A1C Slides Found: 414
Effect of Early Thiazolidinedione Therapy on A1C Levels
Effect of Early Thiazolidinedione Therapy on C-Peptide Levels
Effect of Early Thiazolidinedione Therapy on Diabetes Onset
Meta-Analysis: A1C and CVD in Type 2 Diabetes
Glycemic Control and Risk of Development of Heart Failure in Diabetes
Pioglitazone Decreases Carotid IMT Independent of Glycemic Control in Patients With Type 2 Diabetes
Exenatide: Effects on Glycemic Control in Combination With Current Oral Therapies
Exenatide: Proportion of Patients Achieving A1C <=7%
Pramlintide Adjunctive Therapy Offers Long-Term Glycemic Control
Effect of Pramlintide Adjunctive Therapy on Weight in Patients With Type 2 Diabetes
Adverse Events Associated With Thiazolidinedione Treatment
GLP-1 Infusion Improves Beta-Cell Insulin Secretion
Vildagliptin Monotherapy Improves Glycemic Control in Type 2 Diabetes
Inadequate Achievement of ADA Goals Among US Adults With Diabetes
Drug Nonadherence Is Associated With Adverse Clinical Outcomes in Diabetes
Sitagliptin Improves Glycemic Control in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Sitagliptin Enhances Glycemic Control, beta-Cell Function in Patients With Type 2 Diabetes Not Controlled With Metformin
ADOPT: Achievement of A1C Levels <7%
Vildagliptin + Pioglitazone Improves A1C in Patients Not Controlled With Thiazolidinedione Monotherapy
Change in A1C for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Sitagliptin + Metformin Improves 24-Hour Glycemic Control
Vildagliptin: Change in Mean A1C During 24-Week Treatment
Vildagliptin: Percentage of Patients Achieving A1C <7%
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Body Weight
24-Week Sitagliptin Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes
UKPDS: Progressive Deterioration in Glycemic Control Over Time
18-Wk Sitagliptin Monotherapy Improves b-Cell Function
18-Wk Sitagliptin Monotherapy Improves Glycemic Control
Effect of Sitagliptin Monotherapy on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin Monotherapy on 2-Hour Postprandial Glucose in Patients With Type 2 Diabetes
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Pioglitazone
Changes in A1C Subgroups for Sitagliptin vs Glipizide in Patients Not Controlled With Metformin
Patients Achieving ADA A1C Goal on 18-Wk Sitagliptin Monotherapy
Effect of Exenatide + TZD on Body Weight in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on A1C in Patients With Type 2 Diabetes
Effect of Sitagliptin + Metformin on FPG in Patients with Type 2 Diabetes
RECORD: Study Design
RECORD: Effect of Rosiglitazone or Metformin Add-on to Sulfonylurea on A1C and FPG
RECORD: Effect of Rosiglitazone or Sulfonylurea Add-on to Metformin on A1C and FPG
Effect of Sitagliptin + Metformin on B-Cell Function at 24 Weeks
Effects of Exenatide LAR on A1C in Patients With Type 2 Diabetes
Effects of Exenatide LAR on Weight in Patients With Type 2 Diabetes
GLAI: Comparison of TZDs on Lipoprotein Subclass Particle Size
Frequent Adverse Events in Diabetic Patients Treated With GLP-1 Analogues
Frequent Adverse Events in Diabetic Patients Treated With DPP-4 Inhibitors
Change in A1C for GLP-1 Analogues vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults
Change in A1C for DPP-4 Inhibitors vs Control in Diabetic Adults (cont)
Change in Body Weight Following 82 Weeks of Exenatide Treatment
Vildagliptin Is as Effective as Rosiglitazone in Lowering A1C but Without Weight Gain in Drug-Naïve Patients With T2D
Sustained Reduction in A1C During 1-Yr Treatment With Vildagliptin in Patients With T2D
Prevalence of IFG in Nondiabetic US Adolescents (Aged 12–19 Yrs)
Glycemic Control With Addition of Sitagliptin to Glimepiride and/or Metformin
PROactive: Time to Main Secondary Composite Endpoint (Death, Nonfatal MI, or Stroke)
PROactive: Time to Primary Composite Endpoint
ADVANCE: Study Design
ADVANCE: Death from Any Cause
ADVANCE: Primary Endpoints
ADVANCE Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ADVANCE Trial: Combined Major Macrovascular and Microvascular Events
ADVANCE Trial: Risk for Major Macrovascular and Microvascular Events
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: A1C
PROactive: Objective/Endpoints
Once-Weekly Exenatide LAR vs Twice-Daily Exenatide for Type 2 Diabetes: A1C Categories
Alogliptin Monotherapy: A1C
Alogliptin and Glyburide Combination Therapy: A1C
Alogliptin Added to Metformin: A1C
Alogliptin Added to Insulin: A1C
12-Week Saxagliptin Improves Glycemic Control in Drug-Naïve Patients
Effect of Sitagliptin vs Rosiglitazone When Added to Metformin Monotherapy
DIGAMI 2: Cumulative Mortality After Acute MI in Type 2 Diabetes
GLAI: Comparison of Pioglitazone vs Rosiglitazone on Glycemic Control
VADT: Comparing Intensive With Standard Glucose Therapy, Primary Outcome
VADT: Comparing Intensive With Standard Glucose Therapy, Secondary Outcomes
VADT: Comparing Intensive With Standard Glucose Therapy, Change in Median A1C
VADT: Comparing Intensive With Standard Glucose Therapy, Adverse Events
Type 2 Diabetes Therapy and Cardiovascular Events: Comparing VADT With Other Trials
ACCORD-MIND: Relationship Between Glycemia Status, Diabetes Duration, and Cognitive Test Scores
ACCORD-MIND: Relationship Between Glycemia Status, CVD, Stroke, Smoking Status, and Cognitive Test Scores
High-Monounsaturated Fat Diet Vs High-Carbohydrate Diet: Effects on A1C, Glucose, Body Weight
GLAI: Enrollment Criteria
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
HEART2D Trial: A1C Values at Each Visit for 60 Months
Retinopathy Stage, Mean A1C, and Mean Systolic Blood Pressure by Ethnicity
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
Alogliptin Study 010, Primary Endpoint: Change in A1C at 26 Weeks
Alogliptin Study 010: Secondary Measurements of A1C at Week 26
Effect of Orlistat on Lipids and Glycemic Control in Patients
Impact of Higher Heart Rate on Development of Cardiometabolic Risk Factors After 20 Years
Effect of Sibutramine on Weight Loss in Obese Patients With Type 2 Diabetes Treated With Sulfonylurea
Improved Glycemic Control When Adding Metformin to Insulin Therapy
RECORD: Study Design
ADOPT: Cumulative Incidence of Monotherapy Failure at 5 Years
RECORD: Conclusion
Meta-Analysis: Intensive vs Standard Glucose Treatment on A1C Concentration at Follow-Up
Meta-Analysis: Intensive vs Standard Glucose Treatment on Non-Fatal Myocardial Infarc
Meta-Analysis: Intensive vs Standard Glucose Treatment on CHD
Meta-Analysis: Conclusion
Vildagliptin vs Rosiglitazone Monotherapy in Type 2 Diabetes: Effects on Lipids
ACCORD: Annual Incidence of Hypoglycemia in the Intensive Versus Standard Treatment Groups
ACCORD: Hypoglycemia and Mortality
VADT: Primary Endpoint
VADT: Effect of BMI on Rates of Severe Hypoglycemia
Saxagliptin for Treatment of Type 2 Diabetes: Design
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in A1C from Baseline to Week 24
Saxagliptin for Treatment of Type 2 Diabetes: Mean Change in FPG from Baseline to Week 24
Effect of Mediterranean-Style Diet on Need for Diabetes Therapy
ADVANCE Substudy: Effects of BP Lowering and Intensive Glucose Control on Retinopathy
Sitagliptin Improves A1C in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Reduces FPG in Patients With Type 2 Diabetes Not Controlled With Metformin
Effect of Sitagliptin on 2-Hour Post-Meal Plasma Glucose in Patients With Type 2 Diabetes Not Controlled With Metformin
Sitagliptin Monotherapy Reduces FPG in Patients With Type 2 Diabetes
Effect of Exenatide + TZD on Blood Glucose in Patients With Type 2 Diabetes
Steno-2: Percentage of Patients at Treatment Goals at End of Study
Effect of Sitagliptin Added to Glimepiride and/or Metformin in Patients With Type 2 Diabetes
Effect of Vildagliptin Added to Glimepiride on ß-Cell Function in Patients With Type 2 Diabetes
ACCORD: Study Design
Once-Weekly vs Twice-Daily Exenatide in Type 2 Diabetes: Body Weight
Fasting Levels of Intact GIP and GLP-1 Concentrations and DPP-4 Activity in Patients With Diabetes
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results A1C Reduction
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
Liraglutide Vs Sitagliptin for Type 2 Diabetes: 1-Year Results
Alogliptin Study 010, Secondary Efficacy Endpoint at Week 26: Hyperglycemia
High-Normal A1C as a Type 2 Diabetes Predictor: Design
High-Normal A1C as a Type 2 Diabetes Predictor: Results
Alogliptin Study 010: Exploratory Endpoints of Alogliptin Therapy vs Placebo
San Luigi Gonzaga Diabetes Study: Results
Alogliptin Study 010: Safety
Vildagliptin vs Metformin: A1C
ACCORD: A1C and Mortality Risk
Liraglutide Vs Sigagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: Design
Liraglutide Vs Sitagliptin for Type 2 Diabetes Inadequately Controlled With Metformin: A1C
LOADD: Nutritional Intervention for Persistent, Treated Hyperglycemia
LOADD: Primary Endpoint—Difference in A1C at 6 Months
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Design
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Change in A1C from Baseline to Week 52
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
STAMPEDE: Design
STAMPEDE Results: Primary Endpoint (A1C ≤6%) at 12 Months
Meta-analysis: Effects of GLP-1 Receptor Agonists on Weight Loss - Additional Results
ACP: Considerations for Oral Pharmacologic Therapy in Type 2 Diabetes
ORIGIN Trial: Design
ORIGIN Trial: Baseline Characteristics (1 of 2)
ORIGIN Trial: Baseline Characteristics (2 of 2)
ORIGIN Trial: Results
Trends in CHD Risk Among Adults With Diabetes: Results
TODAY Study: Primary Outcome—Loss of Glycemic Control
TINSAL-T2D Trial: Design
TINSAL-T2D Trial: Eligibility Criteria and Study Protocol
TINSAL-T2D Trial: Baseline Characteristics
TINSAL-T2D Trial: Primary Outcome—Change in A1C
San Luigi Gonzaga Diabetes Study: Design
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
RECORD: CV Death and Hospitalization
RECORD: Time to Primary Endpoint
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
Diabetic Retinopathy and Sight-Threatening Conditions: Global Prevalence
Diabetic Retinopathy and Sight-Threatening Conditions: Prevalence and Subgroup Data
DURATION-4: Design
DURATION-4: Mean Change in A1C from Baseline to Week 26
EUREXA Trial: Primary Outcome—Time to Treatment Failure
EUREXA Trial: Design and Enrollment Profile
EUREXA Trial: Design
BLOOM-DM: Design
DURATION-4: Additional Outcomes
BLOOM-DM: Secondary Endpoints
DURATION-4: Most Common Adverse Events
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
JUPITER Analysis: Design
JUPITER Analysis: Baseline Characteristics 0 or ≥1 Major Diabetes Risk Factor*
DPPOS Bridge: Year 4
JUPITER Analysis: Risk Reduction With Rosuvastatin ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Risk Reduction With Rosuvastatin No Major Diabetes Risk Factor*
JUPITER Analysis: Conclusions
TODAY Study: Design
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Operative Safety, Waist Circumference
TODAY Study: Eligibility Criteria and Run-in Period
TODAY Study: Baseline Characteristics
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: CV Safety, Glucose, Adverse Events
Look AHEAD: 1-Year Interim Results
EASIE Trial: Safety Population Hypoglycemia and Adverse Events
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Recommendations for Care and Treatment (2 of 3)
RYGB Surgery: Long-Term Health-Related Outcomes Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: Design
Switching from Sitagliptin to Liraglutide After 52 Weeks of Treatment: 26-Week Extension Results for A1C Reduction
Liraglutide Treatment for 78 Weeks: Reductions in A1C from Baseline
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Design
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Change in A1C from Baseline
DURATION-6: Secondary Endpoints
DURATION-6: Adverse Events
Meta-analysis: DPP-4 Inhibitors for Treatment of Type 2 Diabetes—Adverse Events and All-Cause Mortality
ARIC: Role of A1C in Predicting Hypertension—Design
ARIC: Role of A1C in Predicting Hypertension—Results
EUREXA Trial: Change in Body Weight
EUREXA Trial: Hypoglycemia and Adverse Events
EUREXA Trial: Attainment of A1C <7.0% and ≤6.5%
BLOOM-DM: Primary and Secondary Endpoints
Long-term Weight Loss After Roux-en-Y Gastric Bypass
Guidelines for Children and Adolescents With Type 2 Diabetes: Insulin Therapy
Long-term Change in BMI After Roux-en-Y Gastric Bypass
Look AHEAD: Continuous, Sustained Type 2 Diabetes Remission
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Background
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Design
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Primary Endpoint
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: Mean A1C Change
Once-Weekly Exenatide Vs Once- or Twice-Daily Insulin Detemir: A1C Target at Endpoint
Diabetic Retinopathy and Incident CV Events in ACCORD: Results
Weight Gain in ACCORD By Type 2 Diabetes Treatment Allocation
Relationship Between Change in Weight and Change in A1C in ACCORD
Diurnal Pattern to Insulin Action in Type 1 Diabetes: Design
ADA/Endocrine Society: Impact of Hypoglycemia on Glycemic Targets
JUPITER Analysis: Increased Diabetes Risk With ≥1 Risk Factor* at Baseline
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Glycemic Control Results
Roux-en-Y Gastric Bypass Surgery in Type 2 Diabetes and Mild Obesity: Design
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Design
Linagliptin vs Glimepiride for Type 2 Diabetes Not at Goal on Metformin Monotherapy: Change in A1C from Baseline
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
EASIE Trial: Design
EASIE Trial: Study and Enrollment Profile
BP Rates and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes: Results
Efficacy of Twice-Daily Exenatide Added to Basal Insulin for A1C Reduction: Design
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo : A1C Reduction at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Target A1C Levels at 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Body Weight 30 Wks
Twice-Daily Exenatide Added to Basal Insulin Vs Placebo: Hypoglycemia at 30 Wks
Twice-Daily Exenatide Vs Placebo Added to Basal Insulin: Adverse Events
EASIE Trial: Efficacy Population Primary Outcome at Week 24—Change in A1C from Baseline
EASIE Trial: Efficacy Population A1C <7.0% and <6.5% Week 24
Diabetes Surgery Study: Design
STAMPEDE Metabolic Substudy: A1C Improvement in All Groups at 24 Months
STAMPEDE Metabolic Substudy: Greater Reduction in Truncal Fat with Gastric Bypass Vs Sleeve Gastrectomy
STAMPEDE Metabolic Substudy: Greater Increases in Insulin Sensitivity, Beta-Cell Function with Gastric Bypass
STAMPEDE Metabolic Substudy: Design
DURATION-6: Design
SAVOR-TIMI 53: Saxagliptin Increased Hospitalization for Heart Failure
SAVOR-TIMI 53: Significantly Better Glycemic Control with Saxagliptin
SAVOR-TIMI 53: Safety Endpoints
SAVOR-TIMI 53: Design
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Significantly Greater A1C Change from Baseline with Alogliptin Vs Placebo
DURATION-6: Change in A1C at Week 26
LEAD-3: Liraglutide vs Glimepiride: A1C Level
LEAD-3: Liraglutide vs Glimepiride in Drug-Naïve Patients: A1C
LEAD-3: Liraglutide vs Glimepiride in Previously on Oral Agents: A1
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, Change in A1C at 26 Weeks
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in Patients With Type 2 Diabetes
Liraglutide Reduces A1C Irrespective of Baseline A1C
Liraglutide Enhances Glucose-Dependent Insulin Secretion
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on A1C Levels in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Body Weight in
LEAD-2 Met: Effect of Liraglutide and Glimepiride With Metformin on Fasting Plasma
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on A1
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Body
LEAD-4: Effect of Liraglutide in Combination With Metformin and Rosiglitazone on Fasting
Liraglutide Added to Metformin vs Add-On Therapy With Glimepiride or Placebo, % of Subjects Meeting AACE A1C Goal at 26 Weeks
Guidelines for Children and Adolescents With Type 2 Diabetes: A1C Testing
AleCardio: Time to First Occurrence of Any Part of the Composite of CV Mortality, Nonfatal MI, or Nonfatal Stroke With Aleglitazar Vs Placebo
STAMPEDE: A1C Less Than or Equal to 6.0 Percent at 3 Yrs With Bariatric Surgery Vs Medical Therapy
A1C CVD Outcomes in Adults Without Diabetes | Diabetes Slides | NDEI
A1C No Benefit CVD Risk Predication in Adults Without Diabetes | NDEI
ORIGIN-GRACE: Summary of Findings
Type 2 Diabetes Treatment Intensification Acute MI | NDEI
Type 2 Diabetes Treatment Intensification Albuminuria | NDEI
Type 2 Diabetes Treatment Intensification eGFR Kidney | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes | NDEI
Incretins Pancreatitis Risk Sulfonylureas Type 2 Diabetes Use Duration | NDEI
Incretins Sulfonylureas Pancreatitis Risk Type 2 Diabetes Gender | NDEI
LEAD 6: Change in A1C at 26 Weeks
LEAD 6: Percent at A1C Targets at 26 Weeks
IDF 2012 Type 2 Diabetes Guidelines Screening Diagnosis | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Glycemic Control | NDEI
IDF 2012 Type 2 Diabetes Guidelines Glucose Monitoring | NDEI
CANTATA-D2: Design
IDF Type 2 Diabetes Guidelines In-Patient | NDEI
Emplagliflozin SGLT 2 A1C EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Weight Loss EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 Insulin EMPA-REG MDI Study | NDEI
Empagliflozin SGLT2 Adverse Events EMPA-REG MDI Study | NDEI
Emplagliflozin SGLT 2 EMPA-REG MDI Study | NDEI
Canola Oil Glycemia A1C Type 2 Diabetes | NDEI
Canola Oil Glycemic Control CVD Type 2 Diabetes | NDEI
Canola Oil Study Glycemic Control A1C Type 2 Diabetes | NDEI
Canola Oil Diet Study Glycemia A1C Type 2 Diabetes | NDEI
CANTATA-D2: Canagliflozin Noninferior to Sitagliptin for A1C Lowering at 52 Weeks
CANTATA-M: Significant A1C Reductions with Canagliflozin Vs Placebo at 26 Weeks
No Pancreatic Cancer Signal Saxagliptin DPP-4 SAVOR TIMI | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
CANTATA-M: Greater Proportion of Subjects Achieved A1C <7.0% with Canagliflozin vs Placebo at 26 Weeks
Diabetes Pregnancy Guidelines Endocrine Society Glucose Monitoring | NDEI
Diabetes Pregnancy Guidelines Diabetes Testing Endocrine Society | NDEI
Diabetes Pregnancy Guidelines GDM Testing Endocrine Society | NDEI
Prediabetes Prevalence US Adults 2012 | NDEI
CANTATA-M: Design
HARMONY 3 Albiglutide FPG Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Weight Loss Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide DPP-4 Inhibitor Type 2 Diabetes | NDEI
HARMONY 3 Albiglutide Type 2 Diabetes Metformin | NDEI
GLP-1 Receptor Agonists A1C Type 2 Diabetes | NDEI
Basal Insulin Glycemic Control A1C Type 2 Diabetes | NDEI
HARMONY 3 DPP-4 Inhibitors Safety Pancreatitis | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Macrovascular Slides PPT | NDEI
Look AHEAD at 1 Year: Additional Results
ESH/ESC Hypertension Guidelines: Treatment of Risk Factors Associated With Hypertension
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Macrovascular Death Slides PPT | NDEI
ADVANCE-ON Type 2 Diabetes Study Baseline Characteristics Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission PPT Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission A1C Slide | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Diabetes Medication | NDEI
Diabetes & Aging Study Type 2 Diabetes Remission Summary | NDEI
Look AHEAD: Lifestyle Changes Improve Glycemic Control, CV Risk Factors
BLOOM-DM Lorcaserin Glycemic Effect Type 2 Diabetes | NDEI
ACCORD-MIND Hypoglycemia Brain Structure Type 2 Diabetes | NDEI
Phentermine + Topiramate for Weight Loss in Type 2 Diabetes | NDEI PPT
Look AHEAD: Design
EMPA-REG Blood Pressure Lowering With Empagliflozin Type 2 Diabetes Hypertension | NDEI
EMPA-REG Blood Pressure Reductions With Empagliflozin SGLT2 | NDEI PPT
EMPA-REG A1C & Weight Loss Empagliflozin SGLT2 Type 2 Diabetes | NDEI
EMPA-REG Safety of Empagliflozin in Type 2 Diabetes & Hypertension SGLT2 | NDEI
EMPA-REG BP: A1C, BP, & Weight Reduction With Empagliflozin in Type 2 Diabetes & Hypertension Clinical Significance for HCPs
ADA Type 1 Diabetes Guidelines Diagnostic Criteria | NDEI
ADA/AGS 2012 Consensus Report on Diabetes in Older Adults: Key Facts on Prevalence, Epidemiology
Type 1 Diabetes Diagnosis Follow-Up ADA Guidelines | NDEI PPT
A1C Targets for Nonpregnant Individuals
Glycemic Goals for Adults With Type 1 Diabetes
Glucose Monitoring SMBG CGM ADA Type 1 Diabetes Guidelines | NDEI
A1C Testing ADA Type 1 Diabetes Guidelines | NDEI PPT
A1C Targets Pregnancy ADA Type 1 Diabetes Guidelines | NDEI Slides
Pregnancy Recommendations ADA Type 1 Diabetes Guidelines | NDEI
Diabetes Surgery Study: Greater Number of Subjects Achieved Primary Endpoint with Gastric Bypass Vs Lifestyle & Medical Management
Diabetes Surgery Study: Fewer Medications, Greater Weight Change with Gastric Bypass
EXAMINE: Adverse Events
ADA EASD Treatment Algorithm Type 2 Diabetes | NDEI
ADA EASD Position Statement Insulin Use in Type 2 Diabetes | NDEI
EXAMINE: Design
A1C Reduction GLP-1 RAs & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Similar A1C Goal Achievement GLP-1 RA & Glargine DURATION-3 & LEAD-5 | NDEI
Weight Loss With GLP-1 RA & Increase With Glargine in DURATION-3 & LEAD-5 | NDEI
Hypoglycemia With GLP-1 RA & Insulin in DURATION-3 & LEAD-5 PPT | NDEI
Combination GLP-1 RA & Basal Insulin Treatment Type 2 Diabetes | NDEI
Liraglutide 12-Week Treatment: Effect on Glycemic Control
Canagliflozin & Sitagliptin A1C Type 2 Diabetes ENDO2015 PPT | NDEI
Empagliflozin Vs Linagliptin First-Line Type 2 Diabetes Treatment ENDO2015 | NDEI
Empagliflozin Vs Linagliptin 2nd-Line Therapy Type 2 Diabetes Obesity ENDO2015 | NDEI
AACE 2015 Diabetes Guidelines Glycemic Target A1C PPT | NDEI
AACE 2015 Guidelines Criteria for Diagnosing Type 2 Diabetes PPT | NDEI
AACE 2015 Diabetes Guidelines Prediabetes Diagnosis IFG IGT PPT | NDEI
AACE 2015 Diabetes Guidelines Glucose Values Indicating Prediabetes PPT | NDEI
ADA EASD Position Statement Individualized Glycemic Targets PPT | NDEI
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
TECOS Sitagliptin A1C Efficacy DPP-4 Inhibitor CV Safety | NDEI
Efficacy and Safety of Ranalozine on Glycemia in Type 2 Diabetes
Ranalozine Superior to Placebo for A1C Reduction in Type 2 Diabetes
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
AHA ADA Diabetes Diagnosis Criteria Guidelines PPT | NDEI
A1C Targets AHA ADA Guidelines Type 2 Diabetes CVD Prevention | NDEI
Type 2 Diabetes & CVD Risk AHA ADA Guidelines PPT | NDEI
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD
EMPA-REG OUTCOME Empagliflozin A1C High-Risk Type 2 Diabetes | NDEI
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
AWARD-2: Once-Weekly Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
Lower A1C With Dulaglutide Vs Insulin Glargine AWARD-2 Results | NDEI
Saxagliptin Not Associated With Fractures in SAVOR-TIMI 53 Analysis | NDEI
Safety of Dulaglutide & Insulin Glargine Pancreatitis AWARD-2 | NDEI
Screening for Type 2 Diabetes & Prediabetes in Asymptomatic Individuals
AHA/ACC/TOS Obesity Guidelines: Weight Loss Outcomes in Overweight or Obese Adults
Type 2 Diabetes Treatment Intensification Micro- Macrovascular | NDEI
IDF Guidelines Type 2 Diabetes Diagnosis Older Adults Elderly | NDEI
Pharmacologic Therapy for Type 2 Diabetes ADA Guidelines | NDEI PPT
Type 2 Diabetes Treatment Algorithm ADA Guidelines 2016 | NDEI PPT
Strategies for Insulin Use in Type 2 Diabetes ADA Guidelines | NDEI PPT
SAVOR TIMI Saxagliptin Pancreatitis | NDEI
SAVOR TIMI 53 Pancreatitis Risk Factors Saxagliptin DPP-4 | NDEI
Diabetes Pregnancy Guidelines Endocrine Society GDM A1C | NDEI
HARMONY 3 Albiglutide A1C Type 2 Diabetes | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Linked to Inflammation Slides PPT | NDEI
Edinburgh Type 2 Diabetes Inflammation Doesn't Influence Hypoglycemia Slides PPT | NDEI
VA BEACH DIET Study: Impact of Diet on CVD Risk | NDEI
Phentermine + Topiramate A1C Targets Obese Subjects With Type 2 Diabetes | NDEI
ADA Type 1 Diabetes Guidelines Children and Adolescent Treatment | NDEI
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
Glycemic Control Guidelines to Prevent Diabetic Foot Ulcers A1C PPT | NDEI
Preoperative Workup Metabolic Surgery for Type 2 Diabetes Treatment | NDEI
IRIS Pioglitazone Lowers Rate of Progression to Diabetes Vs Placebo | NDEI
DURATION-3 & LEAD-5 Post-Hoc Analysis Insulin Type 2 Diabetes PPT | NDEI
RYGB Vs Sleeve Gastrectomy for Weight Loss & Glycemic Control ENDO2015 | NDEI
AACE 2015 Guidelines In-Patient Glycemic Targets Critically Ill A1C | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring in the Hospital In-Patient | NDEI
AACE 2015 Diabetes Guidelines Glucose Monitoring CGM SMBG PPT | NDEI
AACE 2015 Diabetes Guidelins Glycemic Targets Pregnancy GDM PPT | NDEI
ACCORD BP Post-hoc Analysis: Design
Insulin Glargine A1C Reduction Type 2 Diabetes PPT | NDEI
Continuous Glucose Monitoring (CGM) Insulin Type 2 Diabetes ADA Guidelines | NDEI
Frequency of A1C Testing for Diabetes Diagnosis ADA Guidelines | NDEI
Glycemic Targets for Adults With Diabetes A1C ADA Guidelines | NDEI
Glycemic Targets for Children With Type 1 Diabetes ADA Guidelines | NDEI
Correlation of A1C With Average Glucose ADA Guidelines | NDEI PPT
Type 2 Diabetes & Prediabetes Screening ADA Guidelines | NDEI PPT
Key Points from TECOS Subanalysis Sitagliptin DPP-4 | NDEI PPT
JUPITER Incident Diabetes Associated With More Risk Factors Rosuvastatin | NDEI
AWARD-2 Design Dulaglutide Vs Insulin Glargine Type 2 Diabetes | PPT
AWARD-2: Lower A1C With Dulaglutide Vs Insulin Glargine Type 2 Diabetes | NDEI
AWARD-2 Similar Adverse Events With Dulaglutide & Insulin Glargine Type 2 Diabetes | NDEI
ORIGINALE A1C Reduction With Insulin Glargine Type 2 Diabetes | NDEI
SAVOR-TIMI 53 Saxagliptin Not Associated With Fracture Risk Diabetes | NDEI